Gbola Amusa
Stock Analyst at Chardan Capital
(1.92)
# 3,047
Out of 4,761 analysts
61
Total ratings
40%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gbola Amusa
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ADVM Adverum Biotechnologies | Downgrades: Neutral | $200 → $50 | $3.94 | +1,169.04% | 2 | Apr 29, 2021 | |
| TSHA Taysha Gene Therapies | Maintains: Buy | $60 → $68 | $1.61 | +4,092.55% | 3 | Apr 13, 2021 | |
| FBRX Forte Biosciences | Maintains: Buy | $2,875 → $2,625 | $10.98 | +23,807.10% | 4 | Mar 17, 2021 | |
| SLDB Solid Biosciences | Maintains: Buy | $188 → $300 | $5.78 | +5,090.31% | 5 | Mar 16, 2021 | |
| PASG Passage Bio | Maintains: Buy | $36 → $45 | $0.52 | +8,474.70% | 3 | Mar 8, 2021 | |
| MCRB Seres Therapeutics | Upgrades: Buy | $28 → $30 | $0.80 | +3,633.67% | 2 | Mar 5, 2021 | |
| QURE uniQure | Maintains: Buy | $85 → $100 | $12.84 | +678.82% | 4 | Mar 2, 2021 | |
| SYBX Synlogic | Maintains: Buy | $75 → $150 | $1.36 | +10,929.41% | 2 | Jan 13, 2021 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $53 → $50 | $5.78 | +765.05% | 3 | Oct 6, 2020 | |
| IMVT Immunovant | Maintains: Buy | $35 → $45 | $21.27 | +111.57% | 3 | Aug 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $115 | $187.86 | -38.78% | 2 | Aug 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $73 → $100 | $47.91 | +108.72% | 1 | Jul 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $84 → $95 | $35.53 | +167.38% | 2 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $15 | $9.19 | +63.22% | 4 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $130 | $7.27 | +1,688.17% | 4 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $100 | $1.82 | +5,394.51% | 6 | Mar 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $2.5 → $2 | $513.22 | -99.61% | 2 | Jan 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $7.31 | - | 3 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $300 → $350 | $700.33 | -50.02% | 6 | Dec 12, 2016 |
Adverum Biotechnologies
Apr 29, 2021
Downgrades: Neutral
Price Target: $200 → $50
Current: $3.94
Upside: +1,169.04%
Taysha Gene Therapies
Apr 13, 2021
Maintains: Buy
Price Target: $60 → $68
Current: $1.61
Upside: +4,092.55%
Forte Biosciences
Mar 17, 2021
Maintains: Buy
Price Target: $2,875 → $2,625
Current: $10.98
Upside: +23,807.10%
Solid Biosciences
Mar 16, 2021
Maintains: Buy
Price Target: $188 → $300
Current: $5.78
Upside: +5,090.31%
Passage Bio
Mar 8, 2021
Maintains: Buy
Price Target: $36 → $45
Current: $0.52
Upside: +8,474.70%
Seres Therapeutics
Mar 5, 2021
Upgrades: Buy
Price Target: $28 → $30
Current: $0.80
Upside: +3,633.67%
uniQure
Mar 2, 2021
Maintains: Buy
Price Target: $85 → $100
Current: $12.84
Upside: +678.82%
Synlogic
Jan 13, 2021
Maintains: Buy
Price Target: $75 → $150
Current: $1.36
Upside: +10,929.41%
Iovance Biotherapeutics
Oct 6, 2020
Maintains: Buy
Price Target: $53 → $50
Current: $5.78
Upside: +765.05%
Immunovant
Aug 25, 2020
Maintains: Buy
Price Target: $35 → $45
Current: $21.27
Upside: +111.57%
Aug 19, 2020
Maintains: Buy
Price Target: $100 → $115
Current: $187.86
Upside: -38.78%
Jul 28, 2020
Maintains: Buy
Price Target: $73 → $100
Current: $47.91
Upside: +108.72%
Jul 15, 2020
Maintains: Buy
Price Target: $84 → $95
Current: $35.53
Upside: +167.38%
Aug 17, 2018
Downgrades: Neutral
Price Target: $19 → $15
Current: $9.19
Upside: +63.22%
Jul 16, 2018
Maintains: Buy
Price Target: $90 → $130
Current: $7.27
Upside: +1,688.17%
Mar 27, 2018
Maintains: Neutral
Price Target: $75 → $100
Current: $1.82
Upside: +5,394.51%
Jan 10, 2018
Upgrades: Neutral
Price Target: $2.5 → $2
Current: $513.22
Upside: -99.61%
Nov 10, 2017
Upgrades: Buy
Price Target: n/a
Current: $7.31
Upside: -
Dec 12, 2016
Upgrades: Neutral
Price Target: $300 → $350
Current: $700.33
Upside: -50.02%